By Prof. Dr Lieven Annemans, expert trainer of the courses
Health Economics for Non-Health-Economists, Basics of Health Economics, and Critical New HTA Developments in Europe: Challenges & Solutions
One of the most underestimated pitfalls in HTA is how treatment effects are presented. The distinction between Relative Risk Reduction (RRR) and Absolute Risk Reduction (ARR) may seem technical, but in practice it can determine whether a product is perceived as valuable or not.
Consider a treatment that reduces event rates from 10% to 8% in comparison with the Standard of Care (SoC):
Below is a simple way to visualise this:

What stands out immediately:
The relative drop looks large, but the absolute difference is small.
Both are correct. Yet they lead to very different interpretations.
HTA bodies focus on ARR because it feeds into the core elements of decision-making:
The gap between RRR and ARR becomes critical when the risk with SoC is low.
A strong RRR can still translate into minimal absolute benefit. This is where some submissions lose credibility with payers.
In contrast, higher-risk populations increase ARR, which improves both:
This explains – together with the aim to reduce budget impact – why HTA bodies often push for more targeted populations.
RRR often makes the effect look impressive.
ARR extrapolated to population level determines whether it matters.
And in HTA, what matters is what gets reimbursed.
Continue your learning from Lieven
If you’d like to learn more from Lieven, CELforPharma also offers a 1-day, hands-on course where you'll learn:
Don’t miss the latest insights from our expert faculty
Subscribe to our newsletter to: